Apontis Pharma AG
XETRA:APPH
Apontis Pharma AG
Cash from Investing Activities
Apontis Pharma AG
Cash from Investing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Apontis Pharma AG
XETRA:APPH
|
Cash from Investing Activities
-€2.9m
|
CAGR 3-Years
-56%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
Cash from Investing Activities
-$53.3m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bayer AG
XETRA:BAYN
|
Cash from Investing Activities
€164m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merck KGaA
XETRA:MRK
|
Cash from Investing Activities
-€3.1B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
13%
|
CAGR 10-Years
-6%
|
|
|
Dermapharm Holding SE
XETRA:DMP
|
Cash from Investing Activities
-€20.8m
|
CAGR 3-Years
42%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
|
PharmaSGP Holding SE
XETRA:PSG
|
Cash from Investing Activities
-€866k
|
CAGR 3-Years
1%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
Apontis Pharma AG
Glance View
APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 176 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.
See Also
What is Apontis Pharma AG's Cash from Investing Activities?
Cash from Investing Activities
-2.9m
EUR
Based on the financial report for Dec 31, 2023, Apontis Pharma AG's Cash from Investing Activities amounts to -2.9m EUR.
What is Apontis Pharma AG's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 3Y
-56%
Over the last year, the Cash from Investing Activities growth was -9%. The average annual Cash from Investing Activities growth rates for Apontis Pharma AG have been -56% over the past three years .
You don't have any saved screeners yet